Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Moleculin Biotech, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 23 | 26 | +3 |
| Shares | 2.96M | 2.98M | +21.8K (+0.7%) |
| Value | $5.26M | $4.32M | −$943.1K (−17.9%) |
New holders (5)
Institutions that held Moleculin Biotech, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jmac Enterprises LLC | 13,132 | $19.0K | 0.00% |
| Urban Wealth Management, LLC | 3,019 | $4.00K | 0.01% |
| UBS Group AG | 1,653 | $2.00K | 0.00% |
| FMR LLC | 17 | $0 | 0.00% |
| Massmutual Trust Co FSB | 167 | $0 | 0.00% |
Sold out (2)
Institutions that held Moleculin Biotech, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Envestnet Asset Management Inc | 10,404 | $19.0K |
| JPMorgan Chase & Co | 594 | $1.00K |